ES2183583T3 - Agente con efecto antidepresivo, que contiene pramipexol y sertralina. - Google Patents

Agente con efecto antidepresivo, que contiene pramipexol y sertralina.

Info

Publication number
ES2183583T3
ES2183583T3 ES99934560T ES99934560T ES2183583T3 ES 2183583 T3 ES2183583 T3 ES 2183583T3 ES 99934560 T ES99934560 T ES 99934560T ES 99934560 T ES99934560 T ES 99934560T ES 2183583 T3 ES2183583 T3 ES 2183583T3
Authority
ES
Spain
Prior art keywords
sertraline
agent
pramipexol
antidepressive effect
antidepressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99934560T
Other languages
English (en)
Spanish (es)
Inventor
Jerzy Maj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical BOEHRINGER INGELHEIM PHARMA
Application granted granted Critical
Publication of ES2183583T3 publication Critical patent/ES2183583T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES99934560T 1998-07-07 1999-07-02 Agente con efecto antidepresivo, que contiene pramipexol y sertralina. Expired - Lifetime ES2183583T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19830201A DE19830201A1 (de) 1998-07-07 1998-07-07 Mittel mit antidepressiver Wirkung

Publications (1)

Publication Number Publication Date
ES2183583T3 true ES2183583T3 (es) 2003-03-16

Family

ID=7873155

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99934560T Expired - Lifetime ES2183583T3 (es) 1998-07-07 1999-07-02 Agente con efecto antidepresivo, que contiene pramipexol y sertralina.

Country Status (33)

Country Link
US (1) US6255329B1 (pt)
EP (1) EP1093369B1 (pt)
JP (1) JP2002520273A (pt)
KR (1) KR100557692B1 (pt)
CN (1) CN1230168C (pt)
AR (1) AR019896A1 (pt)
AT (1) ATE228365T1 (pt)
AU (1) AU762128B2 (pt)
BG (1) BG64972B1 (pt)
BR (1) BR9911768A (pt)
CA (1) CA2336833C (pt)
CZ (1) CZ294087B6 (pt)
DE (2) DE19830201A1 (pt)
DK (1) DK1093369T3 (pt)
EA (1) EA003142B1 (pt)
EE (1) EE04296B1 (pt)
ES (1) ES2183583T3 (pt)
HK (1) HK1037976A1 (pt)
HU (1) HUP0103922A3 (pt)
ID (1) ID27776A (pt)
IL (1) IL140603A0 (pt)
MY (1) MY117969A (pt)
NO (1) NO20010064L (pt)
NZ (1) NZ509729A (pt)
PL (1) PL195043B1 (pt)
PT (1) PT1093369E (pt)
RS (1) RS49795B (pt)
SK (1) SK284923B6 (pt)
TR (1) TR200100146T2 (pt)
TW (1) TW592698B (pt)
WO (1) WO2000002542A2 (pt)
YU (1) YU401A (pt)
ZA (1) ZA200100090B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006162A1 (de) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
PL374310A1 (en) * 2001-12-11 2005-10-03 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
CA2554616A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
ES2334061T3 (es) * 2005-08-15 2010-03-04 University Of Virginia Patent Foundation Neurorrestauracion con pramipexol r(+).
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
EP2341912B1 (en) 2008-09-05 2014-01-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)
CA2760527A1 (en) * 2009-04-30 2010-11-04 Supernus Pharmaceuticals, Inc. Method of treatment of depression
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2812074B1 (en) 2012-02-08 2023-05-10 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
PT3019167T (pt) 2013-07-12 2021-03-04 Knopp Biosciences Llc Tratamento de níveis elevados de eosinófilos e/ou basófilos
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
CN110730662A (zh) 2017-04-10 2020-01-24 才思治疗公司 用于治疗共核蛋白病的nk1-拮抗剂组合和方法
KR20200026920A (ko) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
CN110028464B (zh) * 2019-04-26 2022-11-18 浙江海洋大学 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
EP0186087B1 (de) * 1984-12-22 1989-08-23 Dr. Karl Thomae GmbH Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
JP3947582B2 (ja) * 1995-08-15 2007-07-25 中外製薬株式会社 不安神経症治療剤
JP3118467B2 (ja) * 1996-03-29 2000-12-18 ファイザー インク. 5―ht1aおよび/または5―ht1d受容体の選択的(アンタ)アゴニストとしてのベンジル(イデン)―ラクタム誘導体、その調製法及びその使用法
EP0942732B1 (en) * 1996-12-02 2004-11-17 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating movement disorders
EP1047436B1 (en) * 1998-01-13 2009-10-21 Synchroneuron, LLC N-acetylhomotaurinates for use in treating hyperkinesias

Also Published As

Publication number Publication date
EP1093369B1 (de) 2002-11-27
NO20010064D0 (no) 2001-01-05
KR100557692B1 (ko) 2006-03-07
SK112001A3 (en) 2001-10-08
AU5030399A (en) 2000-02-01
EA200100084A1 (ru) 2001-08-27
RS49795B (sr) 2008-06-05
CZ200177A3 (en) 2001-06-13
BG105112A (en) 2001-10-31
AR019896A1 (es) 2002-03-20
ID27776A (id) 2001-04-26
JP2002520273A (ja) 2002-07-09
EP1093369A2 (de) 2001-04-25
HUP0103922A2 (hu) 2002-03-28
PL195043B1 (pl) 2007-08-31
EE200100014A (et) 2002-06-17
MY117969A (en) 2004-08-30
NO20010064L (no) 2001-03-02
HK1037976A1 (en) 2002-03-01
CA2336833A1 (en) 2000-01-20
DK1093369T3 (da) 2002-12-16
PT1093369E (pt) 2003-03-31
AU762128B2 (en) 2003-06-19
KR20010079491A (ko) 2001-08-22
DE59903556D1 (de) 2003-01-09
US6255329B1 (en) 2001-07-03
ZA200100090B (en) 2002-04-04
BG64972B1 (bg) 2006-11-30
PL345842A1 (en) 2002-01-14
CA2336833C (en) 2008-09-23
EA003142B1 (ru) 2003-02-27
YU401A (sh) 2003-10-31
CN1230168C (zh) 2005-12-07
IL140603A0 (en) 2002-02-10
WO2000002542A3 (de) 2000-06-22
ATE228365T1 (de) 2002-12-15
WO2000002542A2 (de) 2000-01-20
BR9911768A (pt) 2001-04-03
SK284923B6 (sk) 2006-02-02
NZ509729A (en) 2003-06-30
CN1308533A (zh) 2001-08-15
TW592698B (en) 2004-06-21
CZ294087B6 (cs) 2004-10-13
EE04296B1 (et) 2004-06-15
DE19830201A1 (de) 2000-01-13
TR200100146T2 (tr) 2001-07-23
HUP0103922A3 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
ES2183583T3 (es) Agente con efecto antidepresivo, que contiene pramipexol y sertralina.
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
ES2526912T3 (es) Composición farmacéutica que contiene neurotoxina botulínica A2
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
BR0013826A (pt) Formas orais de apresentação
BRPI0507356A (pt) compostos para tingimento de queratina, composições para tingimento de queratina contendo esses compostos e uso de tais composições
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
BR0208142A (pt) Combinações compreendendo um agente antidiarréico e epotilona ou derivado de epotilona
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
BR0114628A (pt) Membro de retenção em microprojeção para aplicador de impacto
UY26850A1 (es) Activadores de la benzeno acetamida glucoquinasa alfa-acil y alfa-heteroátomo sustituida.
DE60124256D1 (de) Aspirin-ausgelöste lipidmediatoren
AR046970A1 (es) Esteres de fosfato de florfenicol
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
HUP0400648A2 (hu) Ecteinascidin-743-t tartalmazó tumorellenes kezeléseknél alkalmazható készítmények
BR0312782A (pt) Composição para o tratamento de manchas
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
BRPI0506631A (pt) combinações de um agente antiemético, composição farmacêutica e usos das combinações
ES2193065T3 (es) Nueva utilizacion del saredutant.
BR0308170A (pt) Composição para limpeza lìquida aquosa, método para limpeza de um substrato, e, uso de um polioxometalato
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
ES2065307T3 (es) Producto y procedimiento para el moldeado permanente del cabello.
AR021463A1 (es) Antibiotico de piridona con perfil de seguridad mejorado
MX9405371A (es) Derivado de naftilo.
AR013559A1 (es) USO DE DERIVADOS DE PIRROLIDINA PARA LA PREPARACIoN DE MEDICAMENNTOS DESTINADOS AL TRATAMIENTO DEL ABUSO DE DROGAS O DE SUSTANCIAS QUE DAN ORIGEN A LA ADICCIoN O AL USO EXCESIVO DE DROGAS , CON EXCEPCIoN DEL ABUSO DEL ALCOHOL, MEDIANTE LA REDUCCIoN DE LA AUTO-MEDICACIoN DE DICHAS DROGAS POR PARTE DE